Important: Both MadeMed and MEDVi facilitate access to compounded prescription medications that are not FDA-approved and have not been evaluated by the FDA for safety or efficacy. This comparison is for educational purposes only. Consult a licensed healthcare provider before starting any prescription treatment. Pricing is subject to change — verify current terms directly on each platform's official website before enrolling.
If you've been researching compounded GLP-1 telehealth programs, you've almost certainly encountered both MadeMed and MEDVi. They're two of the more visible platforms in the current market, they offer overlapping medication formats, and they're both frequently appearing in the same search results. What they don't offer is a side-by-side comparison written by someone who has actually read both platforms' terms, sourced verified pricing, and documented the meaningful differences. That's what this article does.
Company Overview: What Each Platform Is
MadeMed is operated by IDL Health LLC, headquartered in Houston, Texas. Medical services are provided by Xpedicare, LLC, an independent medical group whose licensed clinicians make all prescribing decisions. Medication is dispensed through AbsoluteRx, MadeMed's licensed pharmacy partner. MadeMed holds LegitScript certification. As of available verified sources, no FDA warning letters have been identified for MadeMed as of the date of this review.
MEDVi is a telehealth platform that has been operating since 2023 and is based in Newark, Delaware. Prescriptions are overseen by board-certified U.S. physicians through the OpenLoop Health provider network. Medication is dispensed through Belmar Pharma Solutions, a licensed compounding pharmacy operating since 1985 and accredited by NABP across all its locations. MEDVi holds LegitScript certification and reports serving over 100,000 patients. MEDVi received an FDA warning letter in February 2026, citing misbranding violations — specifically, marketing language the FDA found implied FDA approval and suggested MEDVi was the compounder of the medications it sold. The letter did not allege contaminated or improperly manufactured medications. For our full independent review of MEDVi's platform, see our MEDVi GLP-1 program review.
Verified Pricing Comparison: What Each Platform Actually Charges
The pricing figures below are drawn from publicly available sources verified as of April to May 2026. All prices represent published starting doses. Dose increases typically increase cost. Verify current pricing directly on each platform before enrolling.
Injectable Semaglutide: MadeMed lists $179 per month at the starting dose (0.25mg), inclusive of L-Carnitine, physician consultation, overnight shipping, and injection supplies. MadeMed Club membership ($149/year) reduces this by $10 per month. MEDVi lists $179 for the first month as an introductory rate, then $299 per month for ongoing refills. MEDVi charges no separate membership fee.
Oral Semaglutide (sublingual): MadeMed lists $169 per month at the starting dose (1mg), with 30 sublingual tablets. MadeMed Club reduces this by $10 per month. MEDVi lists oral semaglutide tablets starting at $249 for the first month, then $369 per month ongoing. At every dose tier in available verified data, MadeMed's published oral semaglutide price is lower than MEDVi's.
Injectable Tirzepatide: MadeMed lists $189 per month at the starting dose (2.5mg), inclusive of the same supplies package as semaglutide. MadeMed Club reduces this by $20 per month. MEDVi lists injectable tirzepatide starting at $279 for the first month, then $399 per month ongoing.
Oral Tirzepatide (sublingual): Neither platform has a confirmed published starting price for oral tirzepatide in independently verified sources as of this writing. MEDVi's ongoing rate for compounded tirzepatide (injectable and oral combined into one tier) is reported at $399 per month. Verify oral tirzepatide pricing and current availability directly on each platform. Note: as of January 2026, there is no FDA-approved oral tirzepatide product in any format. Oral tirzepatide from telehealth platforms is a compounded sublingual formulation that has not been evaluated by the FDA.
One structural pricing difference worth understanding: MEDVi bills on a 28-day cycle rather than a calendar month, producing 13 billing events per year rather than 12. At $299 per month for semaglutide, the annual cost is approximately $3,887 — not $3,588 as a 12-month calculation would suggest. MadeMed's billing cycle structure (30-day vs. 90-day subscription options) should be verified directly on the platform.
What's Included: The Bundling Difference
MadeMed explicitly states that its injectable programs include L-Carnitine, physician consultation, overnight shipping, and injection supplies in the listed monthly price. For patients who would otherwise pay separately for these items, the all-in pricing model simplifies cost comparison. MEDVi's pricing includes provider consultation and medication; verify current shipping and supply terms directly on MEDVi's platform, as bundling structures in the telehealth market can change.
The MadeMed Club membership ($149/year) provides monthly discounts of $10 on semaglutide programs and $20 on tirzepatide programs. At the tirzepatide discount rate, the membership pays for itself in approximately 7.5 months. For patients planning a sustained treatment course, the math favors joining. For patients uncertain about long-term commitment, the month-to-month standard pricing avoids the upfront membership cost.
Medication Range: Where the Platforms Diverge
For GLP-1 programs specifically, both platforms offer the same four core formats: injectable semaglutide, oral sublingual semaglutide, injectable tirzepatide, and oral sublingual tirzepatide. MEDVi additionally offers access to brand-name Wegovy and Ozempic at premium pricing tiers for patients who specifically require FDA-approved finished drug products — an option MadeMed does not appear to offer, according to available verified sources.
MadeMed's range extends beyond GLP-1 into categories MEDVi doesn't cover: sermorelin-based peptide therapy in injectable and oral formats, a tadalafil/PT-141/oxytocin men's wellness troche, and NAD+ therapy in injectable and nasal spray formats. For patients whose clinical needs include any of these categories, in addition to weight management, MadeMed offers a single-platform model that MEDVi doesn't match. For our detailed breakdown of MadeMed's peptide and NAD+ programs, see our MadeMed sermorelin and peptide therapy review.
Regulatory History: What the Record Shows
This section matters more in 2026 than it would have in prior years, given the FDA's escalated enforcement posture in the compounded GLP-1 market since September 2025.
MEDVi received a formal FDA warning letter in February 2026. The letter cited misbranding violations specifically — marketing language the agency found implied FDA approval and mischaracterized MEDVi as the compounder of the medications it sold. MEDVi holds active LegitScript certification as of the publication date of this review, and the warning letter did not allege medication contamination or manufacturing deficiencies. Warning letters require a response and corrective action; they do not automatically result in enforcement action or platform shutdown. But they are on the public record, and patients evaluating platforms should know they exist.
No FDA warning letters have been identified for MadeMed in available verified sources as of this writing. This is not a guarantee of future regulatory status — the compounded GLP-1 market remains under active FDA scrutiny, and conditions for all platforms in this space continue to evolve.
Patient Review Volume and Signals
MEDVi has a substantially larger public review footprint: over 10,000 Trustpilot reviews with a 4.4 to 4.5 star average as of early 2026. Common praise focuses on fast approval, clinical team responsiveness, and accessible provider messaging. Common complaints cluster around billing practices and subscription management — a pattern typical of telehealth platforms using auto-renewal subscription models, not a signal specific to clinical quality.
MadeMed has a smaller public review volume, consistent with its relative market age. A smaller review footprint does not indicate lower quality — it reflects how recently a platform entered the market and how aggressively it has solicited public reviews. Evaluate review signals as one data point among several, not as a primary decision factor.
State Availability
MEDVi reports availability in 49 states (North Dakota excluded as of early 2026 data). MadeMed reports availability in approximately 40 states. If your state's availability is a deciding factor, verify both platforms' current service areas directly — state-level availability in the telehealth GLP-1 market changes as platforms adjust to evolving state telehealth regulations.
How to Choose Between Them
If your primary goal is compounded GLP-1 for weight management and you want the lowest published starting price across semaglutide formats, MadeMed's published pricing is lower at every tier in the verified data. If you want access to brand-name FDA-approved GLP-1 options through the same platform, MEDVi offers that and MadeMed does not appear to. If you need peptide therapy or NAD+ alongside a GLP-1 program, MadeMed is the single-platform option. If you want the largest available patient review base as a signal before committing, MEDVi's review volume is substantially larger. If FDA warning letter history factors into your evaluation, MEDVi has one on record from February 2026 and MadeMed does not.
Neither of these is a definitive answer about which platform is better for any individual patient. The right platform is the one whose clinical team, after reviewing your specific health history, determines an appropriate treatment path for you. Both platforms use licensed clinicians for that determination. Both use licensed pharmacy partners for dispensing. Both operate under the same compounded medication regulatory framework. The differences are in pricing structure, medication range, regulatory history, and review volume — all of which are factors you can evaluate before completing an intake form. For our full breakdowns, see the complete MadeMed review and the complete MEDVi review.
Frequently Asked Questions
Is MadeMed or MEDVi cheaper for injectable semaglutide?
Based on published April 2026 pricing, MadeMed lists injectable semaglutide at $179 per month — identical to MEDVi's introductory first-month rate. MEDVi's ongoing monthly rate after the first month rises to $299. MadeMed's published pricing does not clearly distinguish between an introductory and an ongoing rate in the available verified sources; verify current tier pricing directly on each platform before enrolling.
Did MEDVi receive an FDA warning letter?
Yes. MEDVi received an FDA warning letter in February 2026, citing misbranding violations — specifically, marketing language that implied FDA approval and mischaracterized MEDVi as the compounder of the medications it sold. The letter did not allege that the medications were contaminated or improperly manufactured. MEDVi holds an active LegitScript certification as of the publication date of this review.
Which platform offers more medication formats?
Both platforms offer compounded semaglutide and tirzepatide in injectable and sublingual oral formats. MadeMed additionally offers sermorelin peptide therapy (injectable and oral) and NAD+ therapy (injectable and nasal spray). MEDVi offers brand-name Wegovy and Ozempic at premium pricing tiers. The right platform depends on which medications and categories are relevant to your individual situation.
Which platform has more patient reviews?
MEDVi has a substantially larger public review footprint, with over 10,000 Trustpilot reviews and an average rating of 4.4 to 4.5 as of early 2026. MEDVi has been operating since 2023 and reports serving over 100,000 patients. MadeMed has a smaller public review volume reflecting its relative market age. Review volume and scores are useful signals, but should not be the sole basis for a prescribing decision.